Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?

Name: Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
Author: Green, John A

Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer? — المؤلف: Green, John A — Journal of thoracic disease Nov 2018

المؤلف: Green, John A
النشر: Journal of thoracic disease Nov 2018
الوصف: S3837-S3839 p.